SEC Form 4 · accession 0001209191-16-132806
ALDER BIOPHARMACEUTICALS INC · ALDR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark James Litton
Officer — Chief Business Officer
Period of report
Jul 12, 2016
Accepted (ET)
Jul 14, 2016 · 7:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001423824
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 12, 2016 | M | 25,000 | $0.385 | A | 99,567 | D | |
| Common Stock | holding | — | — | — | 28,000 | I | Held in trust for the benefit of Reporting Person's minor child | |
| Common Stock | holding | — | — | — | 28,000 | I | Held in trust for the benefit of Reporting Person's minor child | |
| Common Stock | holding | — | — | — | 28,000 | I | Held in trust for the benefit of Reporting Person's minor child |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.385 | Jul 12, 2016 | M | 25,000 | A | — | Sep 14, 2016 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1The option is fully vested.